Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: Randomized, parallel, open-label, active-controlled study

Journal of Korean Medical Science

Volumn 29, Issue 1, 2014, Pages 90-97

  Lee, Mi Young ^a   Choi, Dong Seop ^b   Lee, Moon Kyu ^c   Lee, Hyoung Woo ^d   Park, Tae Sun ^e   Kim, Doo Man ^f   Chung, Choon Hee ^a   Kim, Duk Kyu ^g   Kim, In Joo ^h   Jang, Hak Chul ⁱ   Park, Yong Soo ^j   Kwon, Hyuk Sang ^k   Lee, Seung Hun ^l   Shin, Hee Kang ^l  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Chonbuk National University Medical School   (South Korea)

^f Hallym University College of Medicine   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h Pusan National University School of Medicine   (South Korea)

ⁱ Seoul National University Bundang Hospital   (South Korea)

^j Hanyang University College of Medicine   (South Korea)

^k The Catholic University of Korea   (South Korea)

^l Bayer Korea Ltd Pharmaceutical   (South Korea)

more..

Author keywords

Acarbose; Diabetes mellitus; Type 2; Voglibose

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INOSITOL; INSULIN; METFORMIN; VOGLIBOSE;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; DIABETES MELLITUS, TYPE 2; VOGLIBOSE;

ACARBOSE; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84900812689     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.1.90     Document Type: Article

References (39)

1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epi-demiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
2. Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Holland-er P, Rendell M. Adjust to target in type 2 diabetes: comparison of a sim-ple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 31: 1305-10.
3. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK; 4-T Study Group. Three-year efficacy of complex insulin regi-mens in type 2 diabetes. N Engl J Med 2009; 361: 1736-47.
4. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hy-perglycaemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the Europe-an Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hy-perglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the Europe-an Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
6. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-84.
7. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsen-ing diabetes. Diabetes Care 2007; 30: 263-9.
8. Abrahamson MJ, Peters A. Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy. Ann Med 2012; 44: 836-46.
9. Raccah D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10: 76-82.
10. Coniff R, Krol A. Acarbose: a review of US clinical experience. Clin Ther 1997; 9: 16-26.
11. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997; 54: 355-68.
12. Fujisawa T, Ikegami H, Inoue K, Kawabata Y, Ogihara T. Effect of two al-pha-glucosidase inhibitors, voglibose and acarbose, on postprandial hy-perglycemia correlates with subjective abdominal symptoms. Metabo-lism 2005; 54: 387-90.
13. Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW. Voglibose (AO-128) is an efficient alpha-glucosi-dase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995; 56: 493-501.
14. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic pa-tients. Diabetes Res Clin Pract 2002; 55: 99-103.
15. Roze S, Valentine WJ, Evers T, Palmer AJ. Acarbose in addition to exist-ing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Curr Med Res Opin 2006; 22: 1415-24.
16. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acar-bose, glibenclamide, or placebo in NIDDM patients: the Essen Study. Di-abetes Care 1994; 17: 561-6.
17. Internaltional Diabetes Federation. Global guideline for type 2 diabetes. Available at http://www.idf.org/global-guideline-type-2-diabetes-2012 [accessed on 19 February 2013].
18. Service FJ, Hall LD, Westland RE, O'Brien PC, Go VL, Haymond MW, Rizza RA. Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in normal subjects. Diabetologia 1983; 25: 316-21.
19. Hwu CM, Ho LT, Fuh MM, Siu SC, Sutanegara D, Piliang S, Chan JC; Asian Acarbose Study Group. Acarbose improves glycemic control in in-sulin-treated Asian type 2 diabetic patients: results from a multination-al, placebo-controlled study. Diabetes Res Clin Pract 2003; 60: 111-8.
20. Kim MK, Suk JH, Kwon MJ, Chung HS, Yoon CS, Jun HJ, Ko JH, Kim TK, Lee SH, Oh MK, et al. Nateglinide and acarbose for postprandial glu-cose control after optimizing fasting glucose with insulin glargine in pa-tients with type 2 diabetes. Diabetes Res Clin Pract 2011; 92: 322-8.
21. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: a placebo-controlled dose-comparison study. Diabetes Care 1995; 18: 817-24.
22. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Dia-betes Care 1995; 18: 928-32.
23. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acar-bose, metformin, or placebo in dietary-treated NIDDM patients: the Es-sen-II Study. Am J Med 1997; 103: 483-90.
24. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K. Therapeutic potentials of acarbose as first-line drug in NID-DM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-7.
25. Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damçi T, Liebl A, Ross SA. Weight beneficial treatments for type 2 diabetes. J Clin Endocri-nol Metab 2011; 96: 3337-53.
26. Gross JL, Kramer CK, Leitão CB, Hawkins N, Viana LV, Schaan BD, Pin-to LC, Rodrigues TC, Azevedo MJ; Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011; 154: 672-9.
27. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, Dahl M. Second-line therapy in patients with type 2 diabetes inadequately con-trolled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011; 5: e35-48.
28. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin anti-diabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-8.
29. Hegele RA, Connelly PW, Palmason C, Jenkins DJ, Wolever TM. Differ-ential response of plasma lipoprotein(a) and apolipoprotein B in NID-DM subjects treated with acarbose. Diabetes Care 1995; 18: 272-3.
30. Wolever TM, Radmard R, Chiasson JL, Hunt JA, Josse RG, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH. One-year acarbose treatment raises fasting serum acetate in diabetic patients. Diabet Med 1995; 12: 164-72.
31. Jenkins DJ, Wolever TM, Jenkins A, Brighenti F, Vuksan V, Rao AV, Cun-nane SC, Ocana A, Corey P, Vezina C, et al. Specific types of colonic fer-mentation may raise low-density-lipoprotein-cholesterol concentrations. Am J Clin Nutr 1991; 54: 141-7.
32. Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tol-erance and type 2 diabetes. Int J Cardiol 2006; 107: 11-20.
33. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of car-diovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94.
34. Hanefeld M. Cardiovascular benefits and safety profile of acarbose ther-apy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007; 6: 20.
35. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
36. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Rus-sell-Jones D, Philotheou A, Francisco AM, et al. Insulin degludec, an ul-tra-longacting basal insulin, versus insulin glargine in basal-bolus treat-ment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bo-lus Type 1): a phase 3, randomised, open-label, treat-to-target non-infe-riority trial. Lancet 2012; 379: 1489-97.
37. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-16.
38. Rosenstock J, Schwartz SL, Clark CM, Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of in-sulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-6.
39. Su JB, Wang XQ, Chen JF, Wu G, Jin Y. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its re-sponse to further treatment with acarbose. Chin Med J (Engl) 2011; 124: 144-7.